This report covers the 8MM (US, France, Germany, Italy, Spain, UK, Japan and Canada) and provides an Excel-based forecast model for the Amyotrophic Lateral Sclerosis (ALS) market through 2029.
The prevalence of ALS is increasing at a steady rate, in line with population growth in the 8MM, at an annual growth rate (AGR) of 0.79%.The diagnosed prevalent cases of ALS across the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Canada) are expected to increase from 74,614 cases to 80,483 cases during the forecast period.
The ALS market across the 8MM was valued at $318 million in 2019. Over the 10-year forecast period, the market is projected to grow at a compound annual growth rate (CAGR) of 15%, reaching $1.28 billion by 2029.A key driver of growth for the ALS market will be the launches of 12 pipeline products during the forecast period. These will contribute $375.3 million in sales by 2029, despite most being anticipated to launch towards the latter end of the forecast period.
The prevalence of ALS is increasing at a steady rate, in line with population growth in the 8MM, at an annual growth rate (AGR) of 0.79%.The diagnosed prevalent cases of ALS across the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Canada) are expected to increase from 74,614 cases to 80,483 cases during the forecast period.
The ALS market across the 8MM was valued at $318 million in 2019. Over the 10-year forecast period, the market is projected to grow at a compound annual growth rate (CAGR) of 15%, reaching $1.28 billion by 2029.A key driver of growth for the ALS market will be the launches of 12 pipeline products during the forecast period. These will contribute $375.3 million in sales by 2029, despite most being anticipated to launch towards the latter end of the forecast period.
Key Highlights
- Report deliverables include a Pdf report and an Excel-based forecast model
- Forecast includes the 8 major markets (8MM)
- Forecast covers the period 2019-2029.
- 2019 base year sales within the ALS market are approximately $318M across the 8MM detailed in this report. The analyst estimates that the ALS market will grow at a compound annual growth rate (CAGR) of 15% to reach $1.28billion by the end of the forecast period.
Scope
- Overview of ALS, including epidemiology, symptoms, diagnosis, and disease management.
- Annualized ALS therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2019 to 2029.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the ALS market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for ALS. The most promising candidates in late-stage development are profiled.
- Analysis of the current and future market competition in the 8MM ALS therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 8MM ALStherapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the ALS therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
- Abbreviations
- Related Reports
- Executive Summary
- Disease Overview
- Overview of ALS
- Etiology of ALS
- Pathophysiology of ALS
- Classification of ALS
- ALS SWOT Analysis
- Epidemiology
- Total Prevalent Cases of ALS, Both Sexes, Ages ≥40 Years, 2019-29
- Age-Specific Trends in the Total Prevalent Cases of ALS, Both Sexes, 2019
- Sex-Specific Total Prevalent Cases of ALS, Both Sexes, Ages ≥40 Years, 2019
- Total Prevalent Cases of ALS by Type, Both Sexes, Ages ≥40 Years, 2019
- Diagnosed Prevalent Cases of ALS, Both Sexes, Ages ≥40 Years, 2019-29
- Age-Specific Trends in the Diagnosed Prevalent Cases of ALS, Both Sexes, 2019
- Sex-Specific Diagnosed Prevalent Cases of ALS, Both Sexes, Ages ≥40 Years, 2019
- Diagnosed Prevalent Cases of ALS by Type, Both Sexes, Ages ≥40 Years, 2019-29
- Sources and Methodology for ALS Prevalence
- Sources and Methodology for Total and Diagnosed Cases of ALS by Type
- Sources and Methodology for Diagnosed Prevalent Cases of ALS
- Sources and Methodology for Total Prevalent Cases of ALS
- Sources and Methodology for Total and Diagnosed Prevalent Cases of ALS by Type
- Current Treatment Options
- Treatment Paradigm
- Marketed Products
- Product Profile: Riutek (riluzole)
- Product Profile: Exservan (riluzole oral film)
- Product Profile: Tiglutik (riluzole oral suspension)
- Product Profile: Radicava (edaravone)
- Product Profile: Radicava ORS (edaravone oral suspension)
- Product Profile: Qalsody (tofersen sodium)
- Product Profile: Relyvrio (phenylbutyrate and taurursodiol)
- Unmet Needs and Opportunities
- Unmet Needs in ALS
- Earlier Diagnosis is Required
- Identification of Biomarkers
- Continued Need for More Efficacious First-line Treatment Options
- Lack of Disease Modifying Therapies
- R&D Strategies
- R&D Strategies in ALS
- Trends in Clinical Trial Design in ALS
- Trends in Deal-Making in ALS
- Pipeline Assessment
- ALS Pipeline Overview
- Late-Stage Pipeline Agents for ALS
- Product Profile: Masitinib
- Product Profile: NurOwn (debamestrocel)
- Product Profile: TUDCA (Tauroursodeoxycholic acid)
- Product Profile: MN-166 (ibudilast)
- Product Profile: ILT-101 (aldesleukin)
- Product Profile: Ulefnersen sodium
- Product Profile: Pridopidine hydrochloride
- Product Profile: Neuronata-R (lenzumestrocel)
- Product Profile: E-0302 (mecobalamin)
- Product Profile: SLS-005 (trehalose)
- Product Profile: CNM-Au8
- Product Profile: PrimeC (celecoxib + ciprofloxacin)
- ALS: Clinical Trials (Phase II/III) Overview
- Market Outlook
- ALS Market Forecast
- Market Drivers and Barriers
- Appendix
- Primary Research: KOL Information
- Bibliography
- About the Authors
- Contact the Publisher
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Ionis Pharmaceuticals Inc
- Mitsubishi Tanabe Pharma Corp
- MediciNova Inc
- AB Science SA
- Biogen (UK) Ltd
- Italfarmaco SA
- Sanofi
- Iltoo Pharma
- Mitsubishi Tanabe Pharma America Inc
- Corestemchemon Inc
- Seelos Therapeutics, Inc.
- Clene Nanomedicine Inc
- Amylyx Pharmaceuticals Inc
- NeuroSense Therapeutics Ltd
- Prilenia Therapeutics Development Ltd
